Heart failure & cardiomyopathiesSecondary analysis
Diuretic Resistance and the Efficacy of Hydrochlorothiazide in Acute Decompensated Heart Failure: A Post-Hoc Analysis of the CLOROTIC Trial
- Post-hoc analysis of the CLOROTIC randomised trial
Authors' conclusion
The BAN-ADHF score demonstrated good performance in identifying DR, and high DR risk was associated with worse outcomes. HCTZ treatment response on weight loss was similar across DR risk, but improvement in dyspnoea with HCTZ was attenuated in high DR risk.
Study context
- Population
- Patients with acute decompensated HF in the CLOROTIC trial
- Participants
- 220 patients
- Comparison
- Hydrochlorothiazide (HCTZ) vs placebo across diuretic resistance risk
Primary result
As reported in the abstract
HCTZ effect on weight change similar across diuretic resistance (DR) risk, 72 h
pint = 0.75
HCTZ effect on weight change similar across DR risk, 96 h
pint = 0.50
HCTZ improvement in dyspnoea visual analogue scale (VAS) AUC, high vs low DR risk, 72 h
−236 vs. 476 mm; pint = 0.03
HCTZ improvement in dyspnoea VAS AUC, high vs low DR risk, 96 h
−400 vs. 777 mm; pint = 0.001
Further findings
Fluid loss · 72 h
P = 0.003
30-day mortality
P = 0.035
90-day mortality
P = 0.033
BAN-ADHF performance in identifying lowest net diuretic efficiency phenogroup
- AUC
- 0.81
Weight change and VAS AUC by DR risk · 72 h
- Similar across DR risk strata
Original publication
Summarised from the published abstract; every number is checked against it